首頁 > 市場調查報告書 > 製藥

以基因為基之藥物開發

市場調查報告書

商品編碼

1562463

基因組編輯市場規模、佔有率、成長分析、按技術、交付方式、按應用、按模式、按最終用途、按地區 - 行業預測，2024-2031 年

Genome Editing Market Size, Share, Growth Analysis, By Technology (/Cas9, TALENs/MegaTALs), By Delivery Method, By Application, By Mode, By End-use, By Region - Industry Forecast 2024-2031

出版日期: 2024年09月11日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球基因組編輯市場規模為77億美元，從2023年的89.9億美元成長到2031年的311.5億美元，複合年成長率預計將成長16.80%。

基因組編輯涉及透過切割、添加或刪除序列來修改生物體的 DNA，以改變遺傳特徵。該技術旨在透過精確改變細胞基因組來賦予細胞特定的特性。世界各國政府正透過向公共機構、私人公司和學術機構提供資助和獎勵，增加對 KEYWORD 研究的投資。這種不斷增加的支持正在推動預測期內基因組編輯市場的積極成長。有幾個因素促進了基因組編輯市場的擴張。其中包括癌症和遺傳疾病盛行率的上升、對個人化醫療的日益偏好、研發成本的增加以及生物技術和製藥行業的進步。私人和公共資金的激增、測序技術的快速進步以及基因組編輯技術的進步也是關鍵促進因素。 CRISPR技術的採用以及各個生物技術領域對合成基因的需求不斷增加，對該市場產生了重大影響。此外，市場競爭的加劇正在加速基因組編輯市場的成長。例如，Vertex Pharmaceuticals 於 2021 年 4 月與 CRISPR Therapeutics 達成 9 億美元協議，開發和商業化針對 BETA 地中海貧血和鐮狀細胞疾病的 CRISPR-Cas9 基因編輯療法，這證實了其動態性質。此類投資和舉措預計將進一步推動基因組編輯市場的成長。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Merck KGaA（Germany）
Cibus Inc（US）
Recombinetics（US）
Sangamo Therapeutics（US）
Editas Medicine（US）
Precision BioSciences（US）
CRISPR Therapeutics（Switzerland）
Intellia Therapeutics, Inc（US）
Caribou Biosciences, Inc.（US）
Cellectis SA（France）
AstraZeneca（UK）
Takara Bio Inc.（Japan）
Horizon Discovery Ltd.（Revvity, Inc.）（UK）
Danaher Corporation（US）
Transposagen Biopharmaceuticals, Inc.（US）
Genscript Biotech Corp（China）
New England Biolabs（US）
OriGene Technologies, Inc.（US）
bluebird bio, Inc（US）
Lonza（Switzerland）
Thermo Fisher Scientific, Inc.（US）

簡介目錄

Product Code: SQSG35J2001

Global Genome Editing Market size was valued at USD 7.70 billion in 2022 and is poised to grow from USD 8.99 billion in 2023 to USD 31.15 billion by 2031, growing at a CAGR of 16.80% during the forecast period (2024-2031).

Genome editing involves modifying an organism's DNA by cutting and adding or removing sequences to alter its genetic traits. This technique aims to endow cells with specific characteristics by making precise changes to their genome. Governments globally are investing more in genome editing research by providing funding and awards to both public and private sectors, as well as academic institutions. This increased support is driving positive growth in the genome editing market during the forecast period. Several factors are contributing to the expansion of the genome editing market. These include the rising prevalence of cancer and genetic disorders, the growing preference for personalized medicine, increased research and development expenditures, and advancements in biotechnology and pharmaceutical industries. The surge in both private and public funding, rapid progress in sequencing technologies, and advancements in genome editing techniques are also key drivers. The market has been significantly influenced by the adoption of CRISPR technology and the growing demand for synthetic genes across various biotechnology fields. Additionally, heightened competition among market players is accelerating the growth of the genome editing market. For example, Vertex Pharmaceuticals' $900 million agreement with CRISPR Therapeutics in April 2021 to develop and commercialize CRISPR-Cas9 gene-edited therapies for beta-thalassemia and sickle cell disease underscores the sector's dynamic nature. Such investments and initiatives are expected to further propel the growth of the genome editing market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Genome Editing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Genome Editing Market Segmental Analysis

Global Genome Editing Market is segmented by Technology, Delivery Method, Application, Mode, End-use, and region. Based on Technology, the market is segmented into (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease, and Others. Based on Delivery Method, the market is segmented into Ex-vivo, and In-Vivo. Based on Application, the market is segmented into Genetic Engineering, and Clinical Applications. Based on Mode, the market is segmented into Contract, and In-house. Based on end use, the market is segmented into Biotechnology and pharmaceutical companies, Academic and government research institutes, and Contract research organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Genome Editing Market

In recent years, governments globally have significantly invested in genomics, which has greatly advanced the field of genome editing. This support has allowed both academic and governmental institutions to conduct extensive research into genome editing and engineering. For example, the Ministry of Innovation, Science, and Industry (Science) awarded a $15 million grant to Genome Canada to fund 11 genomic research projects focused on health, agriculture, and environmental applications. Additionally, provincial governments, businesses, and research partners are contributing a combined total of $29.7 million to these initiatives, including research into ovarian and cervical cancer. These substantial investments have led to a considerable increase in genomics research projects. The resulting advancements and innovations are expected to drive growth in the genome editing market throughout the forecast period. The increased funding and support from various government bodies are fostering a robust research environment, which is likely to accelerate the development of new genome editing technologies and applications.

Restraints in the Global Genome Editing Market

Off-target effects associated with CRISPR-Cas9 are a significant concern in genome editing. The Cas9 enzyme creates double-stranded breaks in DNA, and any unintended nuclease activity can lead to mutations in non-target genes, potentially triggering oncogenesis. CRISPR-Cas9 can tolerate one to three mismatches in its target sequence, which increases the risk of off-target activity. This unintended activity can occur at a high frequency, with up to 50% of mutations happening at sites other than the intended target. For example, CRISPR might inadvertently target tumor suppressor genes or activate oncogenes. These issues have led to challenges in clinical trials, causing some to be halted. Regulatory bodies are now calling for more research to enhance the safety and precision of CRISPR-Cas9 technology.

Market Trends of the Global Genome Editing Market

The COVID-19 pandemic has spurred significant investments from major pharmaceutical and biotechnology companies, as well as from key players in the genomic sector, into vaccine research and development. This surge in investment is driven by the heightened demand for vaccines and antiviral treatments, which has placed genome editing and engineering technologies at the forefront of the industry. As a result, these advancements are anticipated to be a major force propelling the growth of the genome editing market in the coming years. The increased focus on developing effective vaccines and therapies underscores the growing importance of genome editing technologies in addressing global health challenges.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Trade Analysis
Supply chain Analysis
Case study Analysis
Patent Analysis
Customer & Buying Criteria Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Genome Editing Market by Technology

Market Overview
(CRISPR)/Cas9
TALENs/MegaTALs
ZFN
Meganuclease
Others

Genome Editing Market by Delivery Method

Market Overview
Ex-vivo
In-Vivo

Genome Editing Market by Application

Market Overview
Genetic Engineering
- Cell Line Engineering
- Animal Genetic Engineering
- Plant Genetic Engineering
- Others
Clinical Applications
- Diagnostics
- Therapy Development

Genome Editing Market by Mode

Market Overview
Contract
In-house

Genome Editing Market by End-use

Market Overview
Biotechnology and pharmaceutical companies
Academic and government research institutes
Contract research organizations

Genome Editing Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cibus Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Recombinetics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sangamo Therapeutics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Editas Medicine (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Precision BioSciences (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CRISPR Therapeutics (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Intellia Therapeutics, Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Caribou Biosciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cellectis S.A (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takara Bio Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Horizon Discovery Ltd. (Revvity, Inc.) (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Transposagen Biopharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genscript Biotech Corp (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
New England Biolabs (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OriGene Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bluebird bio, Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lonza (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments